BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38263537)

  • 1. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
    Garrote M; López-Guerra M; García-Pagán JC; Arellano-Rodrigo E; Ferrer-Marín F; Hernández-Boluda JC; Bellosillo B; Nomdedeu M; Hernández-Gea V; Triguero A; Guijarro F; Álamo J; Baiges A; Turon F; Colomer D; Cervantes F; Alvarez-Larrán A
    Ann Hematol; 2024 Mar; 103(3):737-747. PubMed ID: 38263537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
    Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
    Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombosis in myeloproliferative neoplasms].
    Asakura H
    Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
    Vannucchi AM; Antonioli E; Guglielmelli P; Rambaldi A; Barosi G; Marchioli R; Marfisi RM; Finazzi G; Guerini V; Fabris F; Randi ML; De Stefano V; Caberlon S; Tafuri A; Ruggeri M; Specchia G; Liso V; Rossi E; Pogliani E; Gugliotta L; Bosi A; Barbui T
    Blood; 2007 Aug; 110(3):840-6. PubMed ID: 17379742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
    Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Dellacasa CM; Salmoiraghi S; Delaini F; Rambaldi A; Barbui T
    Exp Hematol; 2009 Sep; 37(9):1016-21. PubMed ID: 19559071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
    Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
    Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
    Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
    De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
    J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
    Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
    Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.